|
|
Post by brentie on May 15, 2015 8:13:28 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 15, 2015 8:47:38 GMT -5
Intersting comments with regards to the $37 price target
|
|
|
|
Post by compound26 on May 15, 2015 9:40:33 GMT -5
Really like the fact they actually surveyed 120 physicians. Also note their comment regarding the Spirometry test.
Separately, in keeping with MNKD’s 1Q commentary that lung function testing was a gating factor for Afrezza uptake, prescribers who did not own a spirometer rated the test a 5/5 burden, compared to a 2.5/5 burden for those who did.
Mannkind commented in their conference call that only 30% of the endos have spirometers. Hope Sanofi and Mannkind can find ways to help alleviate the Spirometry test burden for the endos soon.
|
|
|
|
Post by brentie on May 15, 2015 9:48:06 GMT -5
|
|
|
|
Post by liane on May 15, 2015 9:56:22 GMT -5
brentie - your avatar ----> Awwwhhh! Edit - you changed it  |
|
|
|
Post by brentie on May 15, 2015 9:57:34 GMT -5
brentie - your avatar ----> Awwwhhh! Edit - you changed it OK, I'll put it back. |
|
|
|
Post by mnholdem on May 15, 2015 11:41:52 GMT -5
Really like the fact they actually surveyed 120 physicians. Also note their comment regarding the Spirometry test. Separately, in keeping with MNKD’s 1Q commentary that lung function testing was a gating factor for Afrezza uptake, prescribers who did not own a spirometer rated the test a 5/5 burden, compared to a 2.5/5 burden for those who did. Mannkind commented in their conference call that only 30% of the endos have spirometers. Hope Sanofi and Mannkind can find ways to help alleviate the Spirometry test burden for the endos soon. Deepak stated that he thinks MNKD will remove these equipment obstacles and that he now believes penetration will be four times greater than his previously model.
I also like how he used the phrase "...gating factor..." as in flood gate?
|
|
|
|
Post by petech on May 15, 2015 13:22:27 GMT -5
By his own admission, he was off 400% on projections.
Idiots. This is a good example of why it is best to ignore other people's opinion and come up with your own in the biotech world.
|
|
|
|
Post by compound26 on May 15, 2015 14:00:46 GMT -5
By his own admission, he was off 400% on projections. Idiots. This is a good example of why it is best to ignore other people's opinion and come up with your own in the biotech world. We should give him credit for doing his due diligence (at least he based on his opinion on a survey of the physicians; unlike GS, who would just come out with a price target out of thin air). And also note that this time, Jefferies actually surveyed 120 physicians. 120 physicians is not such a small sample. Note that last time (in March 2015), they only surveyed 16 physicians. See the report below. Analyst: MannKind Afrezza Estimates Are Being Changed 'Based On Physician Feedback' Javier Hasse , Benzinga Staff Writer March 24, 2015 In a report issued Tuesday morning, Jefferies analyst Shaunak Deepak adjusted his estimates for MannKind Corporation 's Afrezza based on physician feedback, in spite of early IMS scripts. According to the analyst, the feedback has made the firm more confident in the long-term sales potential of the rapid acting inhaled insulin. Timeline Jefferies maintained its peak penetration estimates across all subgroups, but is now working under the assumption that Afrezza trajectory will take ten years, rather than six. "As a result of this more gradual sales ramp," they lowered their price target from $10 to $9, while reiterating a Buy rating. Speaking With Experts The research firm spoke with 16 endocrinologists, "none of whom had prescribed Afrezza as of early March. However, feedback suggested strong interest in the drug," so they spoke to two physicians at diabetes centers who had prescribed the drug six and four times, respectively. "Collectively, the feedback suggested that Afrezza could be a desirable option as a first insulin or an alternative to injectable mealtime insulin, but that it will likely take additional time to educate physicians to use Afrezza to its full potential." Read more: www.benzinga.com/analyst-ratings/analyst-color/15/03/5352295/analyst-mannkind-afrezza-estimates-are-being-changed-bas#ixzz3aEcAXBBF |
|
